Case Report| Volume 14, ISSUE 4, e413-e416, August 2016

A Case of Gemcitabine and Cisplatin Chemotherapy in a Patient With Metastatic Urothelial Carcinoma Receiving Hemodialysis

Published:February 08, 2016DOI:
      Gemcitabine and cisplatin (GC) chemotherapy is now preferred as the first-line chemotherapy for urothelial carcinoma.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sternberg C.N.
        • Yagoda A.
        • Scher H.I
        • et al.
        M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
        J Urol. 1988; 139: 461-469
        • von der Maase H.
        • Hansen S.W.
        • Roberts J.T
        • et al.
        Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
        J Clin Oncol. 2000; 18: 3068-3077
        • Sternberg C.N.
        • de Mulder P.H.
        • Schornagel J.H.
        • et al.
        Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
        J Clin Oncol. 2001; 19: 2638-2646
        • Bamias A.
        • Dafni U.
        • Karadimou A.
        • et al.
        Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
        Ann Oncol. 2013; 24: 1011-1017
        • Chang P.Y.
        • Dai M.S.
        • Ho C.L.
        • Yao N.S.
        Administration of gemcitabine and cisplatin in cancer patients with renal failure under hemodialysis.
        J BUON. 2013; 18: 1058-1061
        • Matsumoto K.
        Pharmacokinetics of cisplatin and methotrexate after M-VAC chemotherapy for advanced urothelial cancer in hemodialysis patients.
        Int J Urol. 2008; 15: 949-950
        • Ide H.
        • Satou A.
        • Hoshino K.
        • et al.
        Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
        Urol Int. 2011; 87: 245-247
        • Janus N.
        • Thariat J.
        • Boulanger H.
        • Deray G.
        • Launay-Vacher V.
        Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.
        Ann Oncol. 2010; 21: 1395-1403
        • Kiani A.
        • Köhne C.H.
        • Franz T.
        • et al.
        Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
        Cancer Chemother Pharmacol. 2003; 51: 266-270
        • Masumori N.
        • Kunishima Y.
        • Hirobe M.
        • et al.
        Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
        Jpn J Clin Oncol. 2008; 38: 182-185
        • Abbruzzese J.L.
        • Grunewald R.
        • Weeks E.A.
        • et al.
        A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
        J Clin Oncol. 1991; 9: 491-498
        • Yilmaz B.
        • Kadioğlu Y.Y.
        • Aksoy Y.
        Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography.
        Anal Biochem. 2004; 322: 234-237
        • DeConti R.C.
        • Toftness B.R.
        • Lange R.C.
        • Creasey W.A.
        Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).
        Cancer Res. 1973; 33: 1310-1315
        • Himmelstein K.J.
        • Patton T.F.
        • Belt R.J.
        • Taylor S.
        • Repta A.J.
        • Sternson L.A.
        Clinical kinetics on intact cisplatin and some related species.
        Clin Pharmacol Ther. 1981; 29: 658-664
        • Schellens J.H.
        • Ma J.
        • Planting A.S.
        • et al.
        Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
        Br J Cancer. 1996; 73: 1569-1575
        • Tokunaga J.
        • Kikukawa H.
        • Nishi K.
        • et al.
        Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy.
        Gan To Kagaku Ryoho. 2000; 27 ([In Japanese]): 2079-2085